文献速递冠心病

高敏肌钙蛋白T策略与临床变量在美国多中心队列中的诊断效能

Diagnostic Performance of High-Sensitivity Cardiac Troponin T Strategies and Clinical Variables in a Multisite US Cohort.
PubMed 文献 · Circulation · 2021-01-21

该研究在美国8个中心的前瞻性队列中评估了初始hs-cTnT低于检测限、0/1小时算法及其联合HEART评分对30天主要不良心脏事件的排除效能。结果显示,初始hs-cTnT低于检测限联合低危HEART评分的阴性预测值达99.0%,而0/1小时算法单独或联合HEART评分均未达到>99%的阴性预测值。

要点

  • 初始hs-cTnT低于检测限联合低危HEART评分对30天MACE的阴性预测值为99.0%。
  • 0/1小时hs-cTnT算法单独或联合HEART评分未达到>99%的阴性预测值。
  • 初始hs-cTnT低于检测限单独排除30天MACE的阴性预测值为98.3%。

核心结论

  • 在美国多中心前瞻性队列中,初始hs-cTnT低于检测限联合低危HEART评分对30天MACE具有99%的阴性预测值。
  • 0/1小时hs-cTnT算法单独或联合HEART评分未达到>99%的30天MACE阴性预测值。

研究设计与样本

  • 前瞻性队列研究,在美国8个中心纳入急诊科疑似急性冠脉综合征且心电图无ST段抬高的成人患者。
  • 共1462例参与者具有初始hs-cTnT测量值,其中女性占46.4%(678/1462),黑人占37.1%(542/1462),年龄57.6±12.9岁(均值±标准差)。
  • 采集基线和1小时血样测量hs-cTnT(Roche),治疗医生对hs-cTnT结果盲态前瞻性计算HEART评分,30天MACE(心源性死亡、心肌梗死和冠状动脉血运重建)经裁定。

主要发现

  • 30天MACE发生率为14.4%(210/1462)。
  • 初始hs-cTnT低于检测限(LOQ:6 ng/L)者占32.8%(479/1462),对30天MACE的阴性预测值为98.3%(95%CI 96.7-99.3)。
  • 低危HEART评分联合初始hs-cTnT低于检测限者占20.1%(294/1462),对30天MACE的阴性预测值为99.0%(95%CI 97.0-99.8)。
  • 0/1小时算法在1430例中完成,排除57.8%(826/1430),对30天MACE的阴性预测值为97.2%(95%CI 95.9-98.2)。
  • 0/1小时算法联合低危HEART评分排除30.8%(441/1430),对30天MACE的阴性预测值为98.4%(95%CI 96.8-99.4)。

关键数值与推荐

  • 初始hs-cTnT低于LOQ(6 ng/L)联合低危HEART评分对30天MACE的阴性预测值为99.0%(95%CI 97.0-99.8)。
  • 0/1小时hs-cTnT算法对30天MACE的阴性预测值为97.2%(95%CI 95.9-98.2)。
  • 0/1小时算法联合低危HEART评分对30天MACE的阴性预测值为98.4%(95%CI 96.8-99.4)。

临床怎么用

  • 对于急诊科疑似急性冠脉综合征且心电图无ST段抬高的患者,初始hs-cTnT低于检测限联合低危HEART评分可用于排除30天MACE,阴性预测值达99.0%。
  • 0/1小时hs-cTnT算法单独或联合HEART评分未达到>99%的阴性预测值,临床使用时需注意其排除效能。

局限性

  • 研究未报告除设计外的其他局限性信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: European data support the use of low high-sensitivity troponin (hs-cTn) measurements or a 0/1-hour (0/1-h) algorithm for myocardial infarction to exclude major adverse cardiac events (MACEs) among patients in the emergency department with possible acute coronary syndrome. However, modest US data exist to validate these strategies. This study evaluated the diagnostic performance of an initial hs-cTnT measure below the limit of quantification (LOQ: 6 ng/L), a 0/1-h algorithm, and their combination with history, ECG, age, risk factors, and initial troponin (HEART) scores for excluding MACE in a multisite US cohort. METHODS: A prospective cohort study was conducted at 8 US sites, enrolling adult patients in the emergency department with symptoms suggestive of acute coronary syndrome and without ST-elevation on ECG. Baseline and 1-hour blood samples were collected, and hs-cTnT (Roche; Basel, Switzerland) was measured. Treating providers blinded to hs-cTnT results prospectively calculated HEART scores. MACE (cardiac death, myocardial infarction, and coronary revascularization) at 30 days was adjudicated. The proportion of patients with initial hs-cTnT measures below the LOQ and risk according to a 0/1-h algorithm was determined. The negative predictive value (NPV) was calculated for both strategies when used alone or with a HEART score. RESULTS: Among 1462 participants with initial hs-cTnT measures, 46.4% (678 of 1462) were women and 37.1% (542 of 1462) were Black with an age of 57.6±12.9 (mean±SD) years. MACEs at 30 days occurred in 14.4% (210 of 1462) of participants. Initial hs-cTnT measures below the LOQ occurred in 32.8% (479 of 1462), yielding an NPV of 98.3% (95% CI, 96.7-99.3) for 30-day MACEs. A low-risk HEART score with an initial hs-cTnT below the LOQ occurred in 20.1% (294 of 1462), yielding an NPV of 99.0% (95% CI, 97.0-99.8) for 30-day MACEs. A 0/1-h algorithm was complete in 1430 patients, ruling out 57.8% (826 of 1430) with an NPV of 97.2% (95% CI, 95.9-98.2) for 30-day MACEs. Adding a low HEART score to the 0/1-h algorithm ruled out 30.8% (441 of 1430) with an NPV of 98.4% (95% CI, 96.8-99.4) for 30-day MACEs. CONCLUSIONS: In a prospective multisite US cohort, an initial hs-cTnT below the LOQ combined with a low-risk HEART score has a 99% NPV for 30-day MACEs. The 0/1-h hs-cTnT algorithm did not achieve an NPV >99% for 30-day MACEs when used alone or with a HEART score. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02984436.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Allen BR, Christenson RH, Cohen SA, et al. Diagnostic Performance of High-Sensitivity Cardiac Troponin T Strategies and Clinical Variables in a Multisite US Cohort. Circulation. 2021. PMID: 33474976. doi:10.1161/CIRCULATIONAHA.120.049298

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。